This is a great article for anyone who is interested in the science of neuroblastoma. Nate had MYCN amplification at diagnosis, which is what made him "high risk" and the reason he received such intense treatment. Near the end of the article they talk about promising new treatments targeting the MYCN gene, one of which is DFMO (the phase II trial drug Nate is currently taking). We are so grateful for this opportunity for Nate!
No comments:
Post a Comment